PCR Trustee Søren Fryland Møller and Dr Fiona Pathiraja Donate £250,000 to Advance Prostate Cancer Research.

[LONDON, UK] – Prostate Cancer Research (PCR) is proud to announce a landmark £250,000 philanthropic gift from PCR trustee Søren Fryland Møller and his wife Dr Fiona Pathiraja.

This generous donation will advance the charity’s work to drive groundbreaking research and treatments. It will also accelerate the development of Prostate Progress – a first-of-its-kind, patient-centred data platform.

As the most commonly diagnosed cancer in men, prostate cancer demands research at national scale, and while research has significantly improved survival rates, crucial data on diagnosis, treatment pathways, and lived experiences remains scattered across the NHS and disconnected from real-world patient experiences.

By linking patient-reported data directly with NHS records, Prostate Progress will enable understanding of Prostate cancer pathways and empower patients and clinicians.

Søren Fryland Møller is Managing Director of IPQ Capital and also a Prostate Cancer Research trustee: a role to which he brings extensive financial services sector experience. His donation highlights his commitment to driving the charity’s strategic goals forward.

“As a Trustee, I have seen first-hand the rigour and ambition that Prostate Cancer Research brings to the table. This gift centred on Prostate Progress is an investment in a future where data and technology can help bridge the gaps in our healthcare system.”

Dr Fiona Pathiraja is a healthtech investor and a former NHS consultant radiologist with deep healthcare ecosystem expertise. Her donation further supports PCR’s mission to advance research and improve outcomes for patients.

“Having worked as an NHS consultant radiologist, I’ve seen many patients with prostate cancer. I’m proud to support PCR in their mission to ensure no patient with prostate cancer is left behind.”

“We are incredibly grateful to Fiona and Søren for their extraordinary generosity and strategic vision. A gift of this magnitude is a game-changer for Prostate Cancer Research.

Having Fiona and Søren invest so significantly in our work is a powerful vote of confidence. This funding allows us to advance Prostate Progress with the speed that patients deserve, turning scattered data into a unified force for better diagnosis and treatment.”

ENDS

Notes to Editors

About Prostate Cancer Research

Prostate Cancer Research is a patient-centric research and information provision charity dedicated to improving and saving the lives of people with prostate cancer. They fund innovative research projects at world-leading institutions, with a specific focus on tackling health inequities, improving treatments, and developing novel drug targets.

The charity’s landmark project, Prostate Progress, is the UK’s first patient-centric data platform powered by NHS data, designed to personalise treatments and accelerate clinical trials.

For more information, please visit: www.pcr.org.uk

About the Donors

• Søren Fryland Møller: Owner & Managing Director of IPQ Capital, a private investment firm based in London and Copenhagen. He is a Trustee of PCR and Vice Chair of London Business School’s Campaign Leadership Board.
• Dr Fiona Pathiraja: Managing Partner of Crista Galli Ventures, a pan-European HealthTech venture capital firm. A former NHS consultant radiologist, she is a Fellow of the Royal College of Radiologists and an advocate for diversity in technology and investment.

Media Contact: Jess Farmery [email protected]